Latest Rituxan news
Rituximab Noninferior to Ocrelizumab for Newly Diagnosed Relapsing MS
posted July 6th
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes 
Cretostimogene Promising for High-Risk, Non-Muscle-Invasive Bladder Cancer .jpg)
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV 
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines Related Articles
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death 
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA 
Timing of JAK Initiation, Shingles Vaccine Administration Can Affect Outcomes in RA 
2018 to 2024 Saw Rise in Insurance Denials for Brand-Name Drugs Monthly Specialist Briefings
Stay Connected
